Email from Geoff Leo to Dr. Goodenowe requesting responses to questions for a forthcoming story

Note: The PDF document shows the body of an email from Mr. Leo to Dr. Goodenowe. The email header fields (From, To, Date, Subject) are not reproduced in the copy on file. The Lenczner Slaght response of March 24, 2026, which is part of this record, confirms that the email was sent to Dr. Goodenowe directly on or about March 20, 2026.

---

1. In my research, I have discovered that you have incurred a long series of debts and in some cases court judgements that you have failed to honour. This appears to be a pattern of making promises that you don’t keep in your financial dealings. How do you respond to that?

2. Between 2007 and 2009, the Saskatchewan government through Victoria Park Capital invested $6.9M in your company Phenomenome. In 2012, the government determined that investment was worth $0. What is your assessment as to why the Saskatchewan government made that decision?

3. In that Feb. 13 presentation you said your Moose Jaw clinical trials facilities “are in the final construction phase.” Can you please tell me your expected completion date.

4. You have said that you intend to have two MRIs in your clinical trials centre. Given that you are not a doctor and have emphasized that you have no medical staff working in your facilities, are you authorized to operate MRIs?

5. The clinical trials facility building is currently owned by 4089074 Manitoba Ltd. Is that company connected in any way to this medical facility that you are establishing?

6. In that same Feb. 13 presentation, you also said “A purpose-built, FDA compliant drug manufacturing facility is in the final construction phase in Moose Jaw. It will manufacture supplements as drugs.” What is the expected completion date of this drug manufacturing facility?

7. What regulatory steps have you completed that would allow you to manufacture drugs in Canada? What regulatory steps have you completed that would lead to the FDA concluding your facility was “FDA compliant?”

8. You said in your presentation that the clinical trial would begin in 2027 and the newly FDA approved drug ProdromeNeuro would go to market in 2029. Experts I have spoken with say those timelines are very unrealistic. What makes you believe they are reasonable?

9. On October 15, you announced that you were launching a major initiative in China, including 1,000 rehabilitation centres and “100 Dr. Goodenowe branded blood testing and digital brain imaging centres.” That news release, archived below, has since been removed from your website. Why is that? Is this China initiative still happening?

https://web.archive.org/web/20260201124008/https://drgoodenowe.com/dr-dayan-goodenowe-announces-partnership-with-ruiya-group-to-distribute-plasmalogen-precursors-in-china/

10. In an affidavit filed in court and in a Nov. 11, 2015 letter that you sent to shareholders you said of your RCDP drug: “The clinical trial for this life-saving drug is going on right now in the laboratory of PDI.” Yet just a couple of months earlier in an interview with the New York Times you said that you would be applying for an IND, the first step in getting approval for a clinical trial, “next year”. Can you please explain the apparent contradiction? Was there a clinical trial for RCDP going on in 2015 as you said in your affidavit or was it at least a year ago as you indicated to the newspaper?

My deadline is the end of day on Tuesday, March 24. Thank you so much for your help with this.

Geoff

---

Geoff Leo Senior Investigative Reporter | CBC News 2440 Broad Street Regina, Saskatchewan Cell: (306) 533-0906 geoff.leo@cbc.ca Twitter: @gleocbc ca.linkedin.com/in/geoffleo